- Home
- NSRX vs ELUT Comparison
NSRX vs ELUT Comparison
Compare NSRX & ELUT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NSRX | ELUT |
|---|---|---|
| Founded | 2019 | 2015 |
| Country | Israel | United States |
| Employees | 7 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.9M | 42.5M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | NSRX | ELUT |
|---|---|---|
| Price | $3.16 | $0.85 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $19.67 | $6.00 |
| AVG Volume (30 Days) | 11.0K | ★ 46.5K |
| Earning Date | 03-25-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 146.77 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $12,293,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $10.83 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.98 | $0.50 |
| 52 Week High | $9.99 | $2.50 |
Technical Indicators
Market Signals| Indicator | NSRX | ELUT |
|---|---|---|
| Relative Strength Index (RSI) | 44.92 | 44.02 |
| Support Level | $2.83 | $0.89 |
| Resistance Level | $3.60 | $1.00 |
| Average True Range (ATR) | 0.16 | 0.06 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 28.87 | 33.33 |
Price Performance
Historical ComparisonAbout NSRX Nasus Pharma Ltd. Ordinary Shares
Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.
About ELUT Elutia Inc.
Elutia Inc develops proprietary drug-eluting biomatrix products for use in surgical reconstruction and related applications. These products are designed to improve the interaction between implanted medical devices and patients. Its products include CanGaroo, designed for implantable electronic devices, and SimpliDerm, used in soft tissue repair, with functions related to implant support and wound management. The company operates in two segments: Women's Health and Cardiovascular. The majority of revenue is derived from the Women's Health segment.